Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
11:30am, Friday, 25'th Mar 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm
Arcutis to Present at Upcoming Investor Conference
10:30am, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm
Arcutis to Present at Upcoming Investor Conference
10:30am, Wednesday, 02'nd Mar 2022 GlobeNewswire
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.
Arcutis to Present at Upcoming Investor Conference
05:30am, Wednesday, 02'nd Mar 2022
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu
Arcutis Biotherapeutics GAAP EPS of -$1.42 beats by $0.18
10:25pm, Tuesday, 22'nd Feb 2022 Seeking Alpha
Arcutis Biotherapeutics press release (ARQT): Q4 GAAP EPS of -$1.42 beats by $0.18.Strong financial position with more than $385M in cash, cash equivalents, and marketable securities.
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
09:01pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immun
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
09:01pm, Tuesday, 22'nd Feb 2022 GlobeNewswire
WESTLAKE VILLAGE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2021, and provided a business update.
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
01:00pm, Tuesday, 01'st Feb 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu
Arcutis Biotherapeutics (ARQT) Buy Rating Reaffirmed at Mizuho
09:18am, Friday, 24'th Dec 2021 Dakota Financial News
Mizuho reiterated their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT) in a report issued on Thursday morning, TipRanks reports. They currently have a $58.00 price target on the stock. A number of other research firms have also commented on ARQT. Morgan Stanley lowered their price objective on shares of Arcutis Biotherapeutics from $50.00 to []
Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners
01:00pm, Thursday, 23'rd Dec 2021 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu
Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners
01:00pm, Thursday, 23'rd Dec 2021 GlobeNewswire
WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it has obtained a $225 million term loan facility from funds managed by SLR Capital Partners (SLR). This additional capital further strengthens Arcutis balance sheet in advance of a potential 2022 Food and Drug Administration (FDA) approval and launch of topical roflumilast cream in plaque psoriasis, and in advance of three 2022 pivotal clinical data readouts in atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. This non-dilutive financing commitment extends the Companys cash runway into 2024.
Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast
10:17am, Thursday, 23'rd Dec 2021
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has obtained a $225 million term loan facility from SLR Capital Partners (SLR). This additional capital further strengthens Arcutis' balance sheet bef
5 Stocks To Watch For December 23, 2021
10:05am, Thursday, 23'rd Dec 2021 Benzinga
Some of the stocks that may grab investor focus today are:
Banner Corporation (NASDAQ: BANR) reported a buyback of 1.71 million shares, which is the equivalent of around 5% of its common stock. Banne
FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
09:01pm, Wednesday, 22'nd Dec 2021 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu
